Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06582771 · ClinicalTrials.gov registry record · Phase 2

A Study of Sotorasib in People With Non-Small Cell Lung Cancer

A Phase 2 study of Non Small Lung Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
39
Enrollment target
7
Study locations

NCT06582771 is a Phase 2 study of Non Small Lung Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 39 participants. The trial reports 7 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06582771, a Phase 2 study of Non Small Lung Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
39 participants
Enrollment target
7
Study locations

Study Summary

The researchers are doing this study to see if sotorasib is a safe and effective treatment for people with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation who have not received treatment for their cancer since it became advanced. (Participants have not received a "first-line therapy" since their cancer became advanced.)

Conditions Studied

Interventions

  • DRUG Sotorasib

Study Locations (7)

New York

  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) - Commack
  • Memorial Sloan Kettering Westchester - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Nassau - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2024-08-30
Est. Completion 2026-08
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

What the Registry Record Tells You About NCT06582771

The ClinicalTrials.gov registry entry for NCT06582771 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non Small Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Sotorasib is the first listed.

NCT06582771 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.

Frequently Asked Questions

What is clinical trial NCT06582771 about?

NCT06582771 is a clinical study titled "A Study of Sotorasib in People With Non-Small Cell Lung Cancer". The researchers are doing this study to see if sotorasib is a safe and effective treatment for people with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation who have not received treatment for their cancer since it became advanced. (Participants have not received a "first-line th...

What is the current status of trial NCT06582771?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2024-08-30. Estimated completion is 2026-08.

What conditions does trial NCT06582771 study?

This clinical trial studies the following conditions: Non Small Lung Cancer.

What interventions are being tested in trial NCT06582771?

The interventions under investigation include: Sotorasib (DRUG).

Who is sponsoring clinical trial NCT06582771?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06582771 being conducted?

This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.